Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae

Authors:

Abstract
Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistant Enterobacteriaceae (CRE) infections. We describe the in vitro activity of meropenem-vaborbactam against representative CRE genotypes and laboratory-engineered Escherichia coli isolates harboring mutant bla KPC genes associated with ceftazidime-avibactam resistance.
Funding Information
  • HHS | NIH | NIH Clinical Center (K08AI114883)
  • HHS | NIH | NIH Clinical Center (R21AI128338)
  • HHS | NIH | NIH Clinical Center (R21AI111037)
  • HHS | NIH | NIH Clinical Center (R01AI104895, R21AI123747, R21AI135522)

This publication has 30 references indexed in Scilit: